Dr. Robin Parihar
1102 Bates Ave., Suite 1770
Houston, TX 77030
Dr. Robin Parihar is a pediatric hematologist-oncologist with a clinical interest in children with solid tumors such as rhabdomyosarcoma and neuroblastoma. He serves as a member of the Solid Tumor Programs, including the Neuroblastoma Program, and specializes in patients with tumors of the muscle, soft tissue, or kidney. He is board certified by the American Board of Pediatrics in Pediatrics and Pediatric Hematology/Oncology.
MD, Wright State University School of Medicine
PhD, Immunology, The Ohio State University
BS, Chemistry, Wake Forest University
Residency, Cleveland Clinic Children’s Hospital
Fellowship, Baylor College of Medicine
American Board of Pediatrics
American Academy of Pediatrics (AAP)
American Association for Cancer Research (AACR)
American Society of Clinical Oncology (ASCO)
American Society of Pediatric Hematology/Oncology (ASPHO)
Children’s Oncology Group (COG)
Dr. Robin Parihar’s research interests center around finding new ways in which to enhance the body’s own immune system to detect and destroy cancer. He has worked in the field of immunology for over a decade and has contributed to numerous translational research projects investigating the role of natural killer (NK) cells in the control of cancer.
Dr. Parihar’s current research interests center around enhancement of NK cell function with chimeric receptors that target aspects of the solid tumor microenvironment.He conducts research for the Cell and Gene Therapy Program under the guidance of principle investigator, Cliona Rooney, PhD.
His previous work has provided novel insights into the mechanism by which cytokines enhance the activity of NK cells in response to antibody-coated tumors.
Dr. Parihar has served as a principle investigator and collaborator on grants examining NK cells as anti-cancer therapy and published extensively on the subject. Besides his interest in immunology and its relation to cancer, Dr. Parihar also places great importance in the role of the physician at the bedside, as an advocate and communicator for patients and their families. Thus, he has always been interested in clinically‑relevant research, with the ultimate goal of translating basic science discoveries made in the lab into novel clinical treatments for children with cancer.